-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
OBJECTIVE : Clinical trials have repeatedly shown that the addition of glucocorticoids (GCs) to the initial treatment of conventional synthetic (cs) DMARDs is more effective than csDMARDs alone in newly diagnosed rheumatoid arthritis (RA) patient.
Objectives Objective : Clinical trials have repeatedly shown that in newly diagnosed patients, csDMARD alone is more effective in the initial treatment of conventional synthetic (cs) DMARD.
Methods : A systematic literature search was performed to identify observational cohorts and clinical trials of RA patients receiving initial GC bridging therapy (defined as discontinuation of GC therapy within 1 year.
Methods A systematic literature search was performed to identify observational cohorts and clinical trials of RA patients receiving initial GC bridging therapy (defined as discontinuation of GC therapy within 1 year.
RESULTS : A scoping literature search for observational cohort studies found no studies that answered the research questi.
Conclusions The success rate of post-bridging GC termination as part of the initial treatment of RA has been described in a limited number of studie.
van Ouwerkerk L, Palmowski A, Nevins IS , et a.
Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthrit.
Annals of the Rheumatic Diseases2022;81 : 937-94 , et al Annals of the Rheumatic Diseases: Leave a comment here
